Prasanthi Ganesa, MD
Hematology & Oncology · Fort Worth, TXNPI 1598794570
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $166,744 of the $204,899 with a category attached, or 81.4%. Daiichi Sankyo Inc. accounts for 71.5% of it on its own, with 41 other manufacturers making up the rest. Among hematology & oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $582.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$147K
- Merck$31K
- AstraZeneca$23K
- Genentech USA, Inc.$1K
- Novartis$593
- E.r. Squibb & Sons, L.L.C.$542
- plus $2K from 36 others
Across 63 payments — averaging $13,217 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tesaro, Inc.$596K
- GSK$232K
- Acerta Pharma LLC$5K
- Merck$31
What the payments were for
- Consulting fees$8,8444%
- Speaking & faculty fees$166,74481%
- Travel & lodging$20,10110%
- Food & beverage$8,5574%
- Education$1550%
- Other$4990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 179 | $146,573 |
| Merck | 38 | $30,712 |
| AstraZeneca | 29 | $23,067 |
| Genentech USA, Inc. | 6 | $1,190 |
| Novartis | 9 | $593 |
| E.r. Squibb & Sons, L.L.C. | 9 | $542 |
| Puma Biotechnology, Inc. | 5 | $309 |
| Lilly USA, LLC | 11 | $299 |
| Gilead | 5 | $180 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $155 |
| Incyte Corporation | 2 | $148 |
| AbbVie | 7 | $140 |
| Bristol Myers Squibb | 4 | $78 |
| GSK | 2 | $56 |
| Boehringer Ingelheim | 2 | $52 |
| Tempus AI, Inc | 2 | $51 |
| Array Biopharma Inc | 2 | $50 |
| Tesaro, Inc. | 3 | $49 |
| Kyowa Kirin, Inc. | 3 | $48 |
| Novocure Inc. | 3 | $45 |
| Foundation Medicine, Inc. | 2 | $42 |
| Seagen Inc. | 3 | $41 |
| Amgen | 2 | $40 |
| Karyopharm Therapeutics Inc. | 2 | $39 |
| Exelixis Inc. | 1 | $38 |
| Pfizer | 2 | $33 |
| Legend Biotech USA Inc. | 1 | $33 |
| EMD Serono, Inc. | 1 | $30 |
| Beigene USA, Inc. | 1 | $25 |
| Geron Corporation | 1 | $25 |
| Servier Pharmaceuticals LLC | 1 | $25 |
| Eisai Inc. | 1 | $25 |
| Cumberland Pharmaceuticals, Inc. | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $22 |
| Sanofi | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Clovis Oncology, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $11 |
| Secura Bio, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$204,899 in reported general payments places this provider in the 95th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 19 | $259,274 |
| ImbruvicaIbrutinib | 13 | $213,145 |
| SancusoGranisetron | 26 | $17,388 |
| EliquisApixaban | 16 | $10,801 |
| Anastrozole | 254 | $4,589 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 38 | $1,107 |
| Letrozole | 41 | $930 |
| Tamoxifen Citrate | 11 | $427 |
| Prochlorperazine Maleate | 30 | $396 |
| Ondansetron OdtOndansetron | 32 | $385 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $296 |
| Gabapentin | 21 | $225 |
| Duloxetine Hcl | 15 | $89 |
| Levothyroxine Sodium | 11 | $86 |
| Ropinirole Hcl | 11 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $593 | $259,27419 claims |
| Cumberland Pharmaceuticals, Inc.Sancuso | $23 | $17,38826 claims |
| PfizerEliquis | $33 | $10,80116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Fort Worth
- Asad DeanFort Worth$1.1M
- Jeremy RossFort Worth$520K
- Asim AhmadFort Worth$130K
- Harris NainaFort Worth$115K
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.